Royal Bank of Canada’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Royal Bank of Canada’s Portfolio MLNT Stock Details MLNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-41,221	Closed	-$22K	–	7322
2019 Q4	$22K	Buy	41,221 +40,793	+9,531%	+$98.9K	﹤0.01%	5824
2019 Q3	$2K	Sell	428 -39,772	-99%	-$143K	﹤0.01%	6364
2019 Q2	$267K	Buy	+40,200	New	+$153K	﹤0.01%	4285
2019 Q1	–	Sell	-7	Closed	–	–	7294
2018 Q4	$0	Sell	7 -148	-95%	-$1.89K	﹤0.01%	7402
2018 Q3	$3K	Buy	155 +124	+400%	+$3.13K	﹤0.01%	6474
2018 Q2	$1K	Buy	31 +26	+520%	+$936	﹤0.01%	6436
2018 Q1	$0	Sell	5 -122	-96%	-$8.02K	﹤0.01%	7060
2017 Q4	$10K	Buy	+127	New	+$9.4K	﹤0.01%	5884

Royal Bank of Canada's MLNT Position: Q1 2020 in Review

Royal Bank of Canada sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 41,221 shares — an estimated $22K sold.

Royal Bank of Canada first reported a position in MLNT in Q4 2017 and held it in 8 quarters. The position peaked at $267K in Q2 2019. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

Royal Bank of Canada reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Royal Bank of Canada sold 41,221 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $22K.
Royal Bank of Canada first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
Royal Bank of Canada's Melinta Therapeutics, Inc. Common Stock position peaked at $267K in Q2 2019.
2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Royal Bank of Canada's 13F filing for Q1 2020, filed 15 May 2020.